Conditions: Postmenopausal Osteoporosis
Keywords: Post Menopausal Osteoporosis MicroCT Amgen denosumab Extreme CT XCT Fosamax Alendronate
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 247
Healthy volunteers: no

Brief summary:
This study is structured to estimate the effect of denosumab, compared to placebo and alendronate, on several bone parameters.

Detailed description:

Arms:
arm 1: Placebo for denosumab and placebo for alendronate arm 2: denosumab and placebo for alendronate arm 3: Placebo for denosumab and alendronate

Interventions: intervention 1: Alendronate intervention 2: Denosumab intervention 3: Placebo
Intervention descriptions: intervention 1: Alendronate 70 mg PO QW intervention 2: denosumab 60 mg SC q 6 mos intervention 3: Placebo for alendronate and placebo for denosumab

Protocol document: